PharmAbcine, non-confidential slide deck Q2 2021

Notice of Changes:

1. The company presented the non-clinical data of PMC-309, one of the company’s first immuno-oncology assets, at AACR 2021. The data shows that PMC-309 has a VISTA-binding mode of action that is distinct from the existing drugs, shows immune boosting effects by inhibiting immunosuppressive MDSCs, and demonstrates higher anti-tumor effect when used in combo with a PD-1 drug.
   
   
2. The company presented the non-clinical data of PMC-403, an antibody that normalizes pathological leaky blood vessels, at ARVO 2021. The data shows that PMC-403 has TIE2-activating mechanism which demonstrates comparable retinal leakage reduction with better optic nerve response than the best-selling competitor in the market.

Thank you for your continued support.

Please check the attached file for details.